Ayurvedic Three-Fruit Formula for Gut Health

How triphala's three-fruit combination supports digestion, gut microbiome diversity, and whole-body wellness through polyphenols and antioxidant compounds

Triphala is a traditional Ayurvedic formula made from equal parts of three dried fruits: amla (Emblica officinalis), bibhitaki (Terminalia bellerica), and haritaki (Terminalia chebula). Used for over 2,000 years in South Asian medicine, it is considered one of the most important herbal preparations in the Ayurvedic pharmacopoeia — valued for supporting digestion, regularity, and overall vitality [1]. Modern research is beginning to explain why: the three fruits together deliver an unusually dense concentration of polyphenols, tannins, and vitamin C that exert antioxidant, anti-inflammatory, and prebiotic effects on the gut [2][3].

How Triphala Works

Each of the three fruits contributes distinct compounds, and together they appear to act synergistically:

Amla (Emblica officinalis) is one of the richest natural sources of vitamin C, along with gallic acid, ellagic acid, and emblicanin A and B. These compounds are potent free radical scavengers and contribute strongly to triphala's antioxidant profile [1].

Bibhitaki (Terminalia bellerica) contains tannins including chebulagic acid and ellagic acid, with demonstrated antimicrobial and anti-inflammatory properties. It has traditional uses for respiratory and digestive complaints.

Haritaki (Terminalia chebula) is rich in chebulic acid, gallic acid, and various tannins. It has mild laxative properties and is especially associated in Ayurveda with supporting the colon and promoting elimination [1][2].

Gut and Microbiome Effects

One of the more compelling modern findings is triphala's prebiotic potential. Polyphenols in triphala are not well-absorbed in the upper GI tract — instead, they pass to the large intestine where gut bacteria metabolize them into bioactive compounds including urolithins, which have their own anti-inflammatory and antioxidant effects [3].

A double-blind, randomized, placebo-controlled pilot trial conducted at UC Davis found that 2,000 mg/day of triphala for 4 weeks produced measurable changes in gut microbiota composition, increasing populations of beneficial Bifidobacterium and Lactobacillus while modulating less desirable species [3]. Fermentation studies using obese human fecal microbiota also showed significant metabolomic changes: triphala treatment up-regulated 305 metabolites involved in amino acid biosynthesis and short-chain fatty acid production [4].

For people with functional GI complaints — constipation, flatulence, mild abdominal discomfort — clinical trials have shown improvements across all of these symptoms with triphala supplementation [2]. Its gentle laxative effect appears to work through restoration of bowel motility rather than irritation, which is why it is traditionally described as a tonic rather than a purgative.

Beyond Digestion

Triphala is also studied for effects extending beyond the gut [1]:

Antimicrobial: Active against a range of bacteria and fungi, including streptococcal species implicated in oral health
Antidiabetic: Haritaki tannins have shown glucose-lowering activity in animal models; human data are limited
Anti-inflammatory: Gallic acid and chebulagic acid inhibit pro-inflammatory signaling pathways (NF-κB)
Radioprotective and chemoprotective: Studied in oncology support contexts; polyphenols may help protect normal cells from oxidative stress

Dosage and Forms

The standard research dose is 500–1,000 mg of standardized extract, or 1–3 grams of whole triphala powder, taken once or twice daily — often in the evening or before bed to support overnight digestive function. It is available as:

Capsules (most convenient; standardized extract)
Powder (traditional; can be mixed into warm water or honey)
Tablets

Triphala has a distinctive bitter, astringent flavor — in traditional use, the taste itself is considered therapeutically relevant. Most people find capsules significantly more palatable. Drink plenty of water when taking triphala in any form.

Precautions: Avoid during pregnancy (particularly haritaki has uterine-stimulating properties traditionally). High doses may cause loose stools initially; start low and increase gradually. Amla's high vitamin C content may interfere with iron absorption if taken simultaneously with iron supplements — space them apart.

See our fermented foods page for more on supporting gut microbiome diversity, or the probiotics page for strain-specific microbiome support.

Evidence Review

Review Literature

Peterson, Denniston, and Chopra (2017) published a comprehensive narrative review of triphala's therapeutic uses drawing on both traditional Ayurvedic texts and modern peer-reviewed literature [1]. The review documented the following bioactivities with varying levels of evidence: free radical scavenging, antioxidant activity, anti-inflammatory, antipyretic, analgesic, antibacterial, antimutagenic, wound healing, anticariogenic, antistress, adaptogenic, hypoglycemic, anticancer, chemoprotective, radioprotective, and chemopreventive effects. While many of these are established only in vitro or in animal models, the breadth of activity reflects the rich polyphenol chemistry of the three-fruit combination.

Tarasiuk, Mosińska, and Fichna (2018) focused specifically on gastrointestinal applications, reviewing available evidence on each of the three component fruits and their relevance to functional GI disorders including IBS [2]. Their review noted that the components of triphala support restoration of the intestinal epithelial lining and, through mild laxative properties, facilitate passage of stool through the colon. They highlighted a clinical trial in which triphala reduced five common GI complaints — constipation, mucous, abdominal pain, hyperacidity, and flatulence — and improved stool frequency, yield, and consistency. The authors concluded that triphala holds promise as an adjunct treatment for IBS, calling for larger randomized controlled trials.

Human Clinical Trial

Peterson et al. (2020) conducted the most rigorous human clinical trial to date: a 4-week, double-blind, randomized, placebo-controlled pilot study in 31 healthy subjects at UC Davis [3]. Participants were randomized to triphala (2,000 mg/day), manjistha (2,000 mg/day), or placebo. Using 16S rRNA gene sequencing of fecal samples, the triphala group demonstrated significant compositional shifts in gut microbiota. Specifically, Bifidobacterium and Lactobacillus — taxa associated with gut barrier integrity and immune modulation — increased relative to placebo. These are the same genera increased by commonly used prebiotic supplements such as inulin and fructooligosaccharides. The triphala effect on microbiome composition was statistically distinguishable from both the manjistha and placebo groups. Alpha diversity (within-sample species richness) trended higher in the triphala group, though the study was underpowered to reach significance on all secondary outcomes.

Microbiome and Metabolomics Research

Kwandee et al. (2023) used an in vitro human gut fermentation model to explore triphala's effects specifically in the context of obesity, using fecal inocula from obese adult women (BMI 35–40 kg/m²) [4]. Batch fermentation with 1 mg/mL triphala extract was analyzed via 16S rRNA sequencing and untargeted metabolomics. While the overall microbial community profile did not shift significantly at the species level within the 24-hour fermentation window, metabolomic analysis revealed 305 significantly up-regulated metabolites compared to control. Pathway analysis indicated activation of phenylalanine/tyrosine/tryptophan biosynthesis — precursor pathways to neurotransmitters including dopamine and serotonin. Additionally, pathways for butyrate production (a beneficial short-chain fatty acid critical for colonocyte health) were enhanced. This metabolomic signature suggests triphala influences the functional output of gut bacteria even in cases where community composition changes are modest.

Strength of Evidence

The evidence base for triphala is moderate for gut/GI applications and weaker (mostly preclinical) for the broader claims often made about it. The 2020 UC Davis RCT provides genuine human clinical evidence for microbiome modulation, though with a small sample size (n=31) and only a 4-week duration. The GI symptom relief data comes largely from one clinical trial and needs replication in larger, multi-site studies. The antioxidant, anti-inflammatory, and antimicrobial activities are well documented in vitro. The main limitation across this field is that most bioactive compounds in triphala are metabolized by gut bacteria before absorption — so efficacy likely depends on individual microbiome composition, making standard dose-response relationships difficult to establish. Triphala's long safety record in traditional use and favorable profile in modern trials support its use as a digestive tonic, with the understanding that the strongest evidence remains for GI benefits.

References

Therapeutic Uses of Triphala in Ayurvedic MedicinePeterson CT, Denniston K, Chopra D. Journal of Alternative and Complementary Medicine, 2017. PubMed 28696777 →
Triphala: current applications and new perspectives on the treatment of functional gastrointestinal disordersTarasiuk A, Mosińska P, Fichna J. Chinese Medicine, 2018. PubMed 30034512 →
Modulatory Effects of Triphala and Manjistha Dietary Supplementation on Human Gut Microbiota: A Double-Blind, Randomized, Placebo-Controlled Pilot StudyPeterson CT, Pourang A, Dhaliwal S, Kohn JN, Uchitel S, Singh H, Mills PJ, Peterson SN, Sivamani RK. Journal of Alternative and Complementary Medicine, 2020. PubMed 32955913 →
Efficacy of Triphala extracts on the changes of obese fecal microbiome and metabolome in the human gut modelKwandee P, Somnuk S, Wanikorn B, Nakphaichit M, Tunsagool P. Journal of Traditional and Complementary Medicine, 2023. PubMed 36970454 →